GUD.TO - Knight Therapeutics Inc.

Toronto - Toronto Delayed Price. Currency in CAD
7.46
-0.06 (-0.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close7.52
Open7.54
Bid7.40 x 0
Ask7.55 x 0
Day's range7.40 - 7.54
52-week range7.10 - 8.69
Volume537,954
Avg. volume210,444
Market cap1.034B
Beta (3Y monthly)0.73
PE ratio (TTM)28.58
EPS (TTM)0.26
Earnings date9 Nov 2016 - 14 Nov 2016
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.43
  • Business Wire

    Medison Urges Knight Therapeutics and Jonathan Goodman to Aggressively Pursue Opportunities Created by Distressed Opioid Case Targets

    Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.5% of Knight Therapeutics, Inc. (GUD.TO) (“Knight” or the “Company”), today commented on the recent claims brought against various pharma companies in the United States and Canada (including against Joddes and Pharmascience, the Goodman family businesses in which Jonathan Goodman, Knight’s CEO, personally owns at least a 25% interest).

  • Business Wire

    Israeli Courts Rule Against Knight Therapeutics’ and Jonathan Goodman in Frivolous and Costly Litigation Aimed at Silencing Medison

    Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.5% of Knight Therapeutics, Inc. (GUD.TO) (“Knight” or the “Company”), received a favorable ruling from Israeli courts in response to a frivolous and costly litigation claim brought by Knight CEO, Jonathan Goodman, against Medison in an attempt to silence Medison with respect to Knight’s lack of performance and poor corporate governance.

  • GlobeNewswire

    Knight Therapeutics Reports Second Quarter 2019 Results

    MONTREAL, Aug. 08, 2019 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today reported financial results for its second quarter.

  • GlobeNewswire

    Knight Therapeutics and pan-Canadian Pharmaceutical Alliance (pCPA) Reach Agreement for PROBUPHINE® for Opioid Dependence

    PROBUPHINE® is the first and only buprenorphine implant approved in Canada for the long-term maintenance management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support1. MONTREAL, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (GUD.TO) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that it has reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent (LOI) regarding  PROBUPHINE® (buprenorphine hydrochloride subdermal implant).

  • GlobeNewswire

    Knight Announces Early Warning Filing Regarding Disposition of Shares of Crescita

    This press release is being disseminated by Knight Therapeutics Inc. ("Knight") (GUD.TO), a specialty pharmaceutical company, as required by National Instrument 62-103 - The Early Warning System and Related Take Over Bid and Insider Reporting Issues regarding the disposition of securities of Crescita Therapeutics Inc. ("Crescita"). The Crescita Shares sold were previously acquired by Knight at an average cost of $0.60 per share. Prior to the dispositions, Knight owned 2,834,689 Crescita Shares representing approximately 13.5% of the outstanding Crescita Shares and 396,000 common share purchase warrants of Crescita (the “Warrants”).

  • GlobeNewswire

    Notice of Knight Therapeutics' Second Quarter 2019 Results Conference Call

    MONTREAL, Aug. 01, 2019 -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its second quarter 2019 financial.

  • Is Knight Therapeutics Inc. (TSE:GUD) Potentially Underrated?
    Simply Wall St.

    Is Knight Therapeutics Inc. (TSE:GUD) Potentially Underrated?

    Knight Therapeutics Inc. (TSE:GUD) is a stock with outstanding fundamental characteristics. When we build an...

  • GlobeNewswire

    Knight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast Cancer

    MONTREAL, July 16, 2019 -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved.

  • GlobeNewswire

    Knight Announces Normal Course Issuer Bid

    Knight Therapeutics Inc. (GUD.TO) (“Knight” or the “Company ”), a leading Canadian specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB").  Pursuant to the NCIB, the Company proposes to purchase, from time to time over the next 12 months, if considered advisable, up to 12,053,693 common shares of the Company, being approximately 10% of its public float of 120,536,931 common shares, as of July 2, 2019. As of July 2, 2019, there were a total of 142,868,687 common shares issued and outstanding.

  • GlobeNewswire

    Knight Announces Filing of New Drug Submission for Ibsrela™ in Canada

    Knight Therapeutics Inc. (GUD.TO) (“Knight”), a Canadian specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Ibsrela™ (tenapanor) has been accepted for review by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C).  Knight and Ardelyx Inc. (NASDAQ:  ARDX) entered into a license agreement in March 2018 granting Knight the exclusive right to commercialize tenapanor in Canada.  “We look forward to bringing Ibsrela, a product with established efficacy and safety, to Canadian patients” said Jonathan Ross Goodman, Chief Executive Officer of Knight.

  • Business Wire

    Medison Establishes Canada’s Only Innovative Pharma Commercial Company

    Medison Biotech (1995) Ltd. (“Medison”), today announced the appointment of Mr. Joe O’Neill as General Manager of Medison Canada. Headquartered in Toronto, Canada, Medison Canada is the only specialized pharmaceutical and biotech company in Canada purely focused on licensing highly innovative, cutting edge therapeutics for patients in need of life saving therapies.

  • Business Wire

    Medison Issues Open Letter to Knight Therapeutics Shareholders Urging Jonathan Goodman to Build Real Business during the Grace Period Knight Received

    Medison Biotech (1995) Ltd. and its affiliates (“Medison”) are collectively the second largest shareholders of Knight Therapeutics, Inc. (“Knight”) holding approximately 7.3% of the share capital of Knight.

  • GlobeNewswire

    Knight has less skin in Medimetriks through full loan repayment

    MONTREAL, June 18, 2019 -- Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Medimetriks Pharmaceuticals.

  • GlobeNewswire

    Knight to Present at the Raymond James Life Sciences and MedTech Conference in New York City

    MONTREAL, June 11, 2019 -- Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, Chief Executive.

  • Is Knight Therapeutics Inc.'s (TSE:GUD) CEO Being Overpaid?
    Simply Wall St.

    Is Knight Therapeutics Inc.'s (TSE:GUD) CEO Being Overpaid?

    The CEO of Knight Therapeutics Inc. (TSE:GUD) is Jonathan Goodman. This report will, first, examine the CEO...

  • GlobeNewswire

    Knight to Present at the Jefferies 2019 Global Healthcare Conference in New York City

    MONTREAL, May 28, 2019 -- Knight Therapeutics Inc. (TSX:  GUD), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, Chief Executive.

  • GlobeNewswire

    Knight to Present at the National Bank Financial Markets 9th Annual Quebec Conference in Toronto

    MONTREAL, May 23, 2019 -- Knight Therapeutics Inc. (TSX:  GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief.

  • GlobeNewswire

    Knight to Present at the 2019 RBC Capital Markets Global Healthcare Conference in New York City

    MONTREAL, May 15, 2019 -- Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, Chief Executive.

  • GlobeNewswire

    Knight Reports First Quarter 2019 Results

    MONTREAL, May 09, 2019 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today reported financial results for its first quarter.

  • GlobeNewswire

    GUD Day for Knight: Shareholders Vote Overwhelmingly in Favour of Management

    Knight Therapeutics Inc. (GUD.TO) ("Knight" or the "Corporation"), a Canadian specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders ("Meeting") held in Montreal, Quebec. Shareholders have voted in favour of all of management’s recommended director nominees listed in the Management Information Circular dated April 4, 2019 (the “Circular”), with the exception of activist nominee Meir Jakobsohn, who was on management’s slate pursuant to a contractual right to be nominated. The Board of Directors is now comprised of: James C. Gale, Jonathan Ross Goodman, Nancy Harrison, Robert N. Lande, Samira Sakhia, Sylvie Tendler, Michael J. Tremblay, and Kevin Cameron.

  • Business Wire

    Medison Creates Significant Change at Knight Therapeutics

    PETACH TIKVA, Israel-- -- Medison’s campaign created unanimous consent that an immediate change is required at Knight and also a collective demand from shareholders that Knight’s leadership create near term value and increase the share price Medison's campaign “rocked the boat” and made Knight leadership commit to implementing required changes that can increase the share price Medison nominee Kevin ...

  • Business Wire

    Medison Campaign Successfully Creates Unanimous Consent for Change at Knight Therapeutics

    PETACH TIKVA, Israel-- -- Medison issues open letter to Knight shareholders, detailing strong momentum for change created by its campaign to end conflicts of interest and revitalize Knight’s strategy If Medison nominees do not achieve majority Board representation, Medison believes nothing meaningful will change at Knight Medison remains committed to ongoing engagement with shareholders to bring necessary ...

  • GlobeNewswire

    Notice of Knight Therapeutics' First Quarter 2019 Results Conference Call

    MONTREAL, May 02, 2019 -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its first quarter 2019 financial.